122 related articles for article (PubMed ID: 17260585)
1. The role of post-implant dosimetry in the quality assessment of prostate implants. The RAH experience.
Marcu L; Quach K
Australas Phys Eng Sci Med; 2006 Dec; 29(4):310-4. PubMed ID: 17260585
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
3. Which patients benefit from post-implant CT dosimetry after real-time intraoperative planning for low dose rate prostate brachytherapy? Case series and systematic literature review.
Mitina N; Christie D; Hill B; Middlebrook N; Nadezhdin N
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):260-7. PubMed ID: 26568444
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo calculated TG-43 dosimetry parameters for the SeedLink 125Iodine brachytherapy system.
Medich DC; Munro JJ
Med Phys; 2003 Sep; 30(9):2503-8. PubMed ID: 14528972
[TBL] [Abstract][Full Text] [Related]
5. Quality indicators and technique for analyzing permanent I-125 prostate seed implants: seven years postimplant dosimetry evaluation.
Marcu LG; Lawson JM; Rutten T; Gowda R
Med Phys; 2012 Jul; 39(7):4123-31. PubMed ID: 22830745
[TBL] [Abstract][Full Text] [Related]
6. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation.
Lindsay PE; Van Dyk J; Battista JJ
Med Phys; 2003 Jul; 30(7):1897-908. PubMed ID: 12906208
[TBL] [Abstract][Full Text] [Related]
7. Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion.
De Brabandere M; Hoskin P; Haustermans K; Van den Heuvel F; Siebert FA
Radiother Oncol; 2012 Aug; 104(2):192-8. PubMed ID: 22857857
[TBL] [Abstract][Full Text] [Related]
8. Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.
Chng N; Spadinger I; Rasoda R; Morris WJ; Salcudean S
Med Phys; 2012 Feb; 39(2):721-31. PubMed ID: 22320782
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric comparison between model 9011 and 6711 sources in prostate implants.
Zhang H; Beyer D
Med Dosim; 2013; 38(2):199-203. PubMed ID: 23510715
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds.
Chen Z; Deng J; Roberts K; Nath R
Med Phys; 2006 Apr; 33(4):968-75. PubMed ID: 16696473
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
12. [Effect of image fusion technology of radioactive particles implantation before and after the planning target and dosimetry].
Jiang YL; Yu JP; Sun HT; Guo FX; Ji Z; Fan JH; Zhang LJ; Li X; Wang JJ
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(29):2275-2279. PubMed ID: 28780842
[No Abstract] [Full Text] [Related]
13. Poor predictive value of intraoperative real-time dosimetry for prostate seed brachytherapy.
Igidbashian L; Donath D; Carrier JF; Lassalle S; Hervieux Y; David S; Bahary JP; Taussky D
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):605-9. PubMed ID: 18793964
[TBL] [Abstract][Full Text] [Related]
14. Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer.
Ishiyama H; Kitano M; Satoh T; Niibe Y; Uemae M; Fujita T; Baba S; Hayakawa K
Radiother Oncol; 2006 Feb; 78(2):194-8. PubMed ID: 16414135
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
16. Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants.
Horwitz EM; Mitra RK; Uzzo RG; Das IJ; Pinover WH; Hanlon AL; McNeeley SW; Hanks GE
Radiother Oncol; 2003 Feb; 66(2):173-9. PubMed ID: 12648789
[TBL] [Abstract][Full Text] [Related]
17. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
[TBL] [Abstract][Full Text] [Related]
18. Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants.
Marcu LG; Lawson JM
Br J Radiol; 2013 Jun; 86(1026):20130058. PubMed ID: 23520225
[TBL] [Abstract][Full Text] [Related]
19. Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy.
Nag S; Shi P; Liu B; Gupta N; Bahnson RR; Wang JZ
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):311-7. PubMed ID: 17996395
[TBL] [Abstract][Full Text] [Related]
20. The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters.
Han BH; Wallner K; Merrick G; Badiozamani K; Butler W
Med Phys; 2003 Jun; 30(6):1096-102. PubMed ID: 12852533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
